Home

Dannielle Appelhans

CIK 1874962 · CEO and President · last filed 2026-09-02

Dannielle Appelhans is a CEO and President who has filed 13 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for HALO, was dated Sep 2, 2026. Across all open-market trades the lifetime net is +$25.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $132.2K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$132.2K

Companies

3

Total Filings

13

Lifetime Open-Market Net

$25.5K

Filer Profile

Reported Address
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
SAN DIEGO, CA 92130
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
HALO Director 1,161 $113.90 $132.2K $0 1 2026-09-02
Generation Bio Co. (GBIO) Delisted Director 0 $5.34 $0 $32.3K 7 2026-02-09
Rubius Therapeutics, Inc. (RUBY) Delisted CEO and President 0 $0.08 $0 -$6.9K 5 2023-02-27

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 HALO Grant (A) +1,161 $0 EDGAR
2026-02-09 Generation Bio Co. (GBIO) Delisted Mixed −1,999 $0 EDGAR
2025-06-06 Generation Bio Co. (GBIO) Delisted Grant (A) — $0 EDGAR
2024-06-10 Generation Bio Co. (GBIO) Delisted Grant (A) — $0 EDGAR
2023-12-11 Generation Bio Co. (GBIO) Delisted Buy (P) +8,000 $14.3K EDGAR
2023-12-06 Generation Bio Co. (GBIO) Delisted Buy (P) +12,000 $18.0K EDGAR
2023-06-12 Generation Bio Co. (GBIO) Delisted Grant (A) — $0 EDGAR
2023-02-27 Rubius Therapeutics, Inc. (RUBY) Delisted Sell (S) −10,385 -$1.3K EDGAR
2023-02-01 Rubius Therapeutics, Inc. (RUBY) Delisted Mixed +3,622 -$970 EDGAR
2022-08-12 Rubius Therapeutics, Inc. (RUBY) Delisted Mixed +6,763 -$4.6K EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.